Do patients frequently report gi problems on darolutamide?

Do patients frequently report GI problems on darolutamide?

Darolutamide is a nonsteroidal androgen receptor inhibitor approved for non-metastatic castration-resistant prostate cancer. In clinical trials, gastrointestinal side effects occurred but were not among the most common adverse events.

How common are GI side effects in the ARAMIS trial data?
The most frequent GI events were diarrhea and nausea. Diarrhea affected 16.9% of patients on darolutamide versus 9.5% on placebo. Nausea occurred in 5.6% versus 5.9%. These rates stayed low overall and did not lead to high discontinuation.

Do real-world patients report more GI issues than trial data suggest?
Post-marketing reports show similar patterns. Diarrhea and nausea remain the leading GI complaints, but serious cases are uncommon. Most patients manage symptoms with supportive care rather than stopping treatment.

What other stomach or bowel problems do patients mention?
Constipation and abdominal pain appear less often than diarrhea. Vomiting is rare. No distinct signal for severe colitis or bowel perforation has emerged in published data.

How do GI side effects compare with enzalutamide and apalutamide?
Enzalutamide lists diarrhea in roughly 10-15% of patients. Apalutamide shows higher rates of diarrhea and rash. Darolutamide’s GI profile sits between the two, with a modest increase over placebo but fewer overall discontinuations.

When do these side effects usually start and how long do they last?
Most GI events begin within the first three months. They are typically mild to moderate and improve with dose interruption or supportive medication. Few patients require permanent discontinuation for GI reasons.

Do any patient groups face higher GI risk?
Older patients and those with prior abdominal radiation or inflammatory bowel disease report slightly higher rates. No clear pharmacokinetic interaction with food or common GI drugs has been identified.

Is there information on long-term GI safety?
Extended follow-up from ARAMIS shows no new GI safety signals after three years. Cumulative incidence of serious GI events stayed under 2%.